Search the Newsreel

AngioDynamics | SCHEDULE 13G/A: Others

This article is a SCHEDULE 13G/A filing for AngioDynamics, indicating an "Others" category. As a regulatory document, it provides required disclosure of beneficial ownership. The provided content indicates "Document", suggesting the full filing is linked or accessible elsewhere.

H.C. Wainwright raises AngioDynamics stock price target on growth

H.C. Wainwright has increased its price target for AngioDynamics (NASDAQ:ANGO) shares to $19 from $16, maintaining a Buy rating, following the company's strong fiscal fourth-quarter and full-year 2026 results. The medical technology firm reported significant growth in net sales, particularly in its Med Tech …

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

A Piper Sandler analyst has initiated coverage on Veracyte Inc. (NASDAQ: VCYT) with an Overweight rating and a $66 price target. This report also details four other analyst initiations for Wednesday, covering companies like Unusual Machines Inc., Deep Fission, Inc., Lantronix Inc., and Tango …

Full Transcript: AngioDynamics Q4 2026 Earnings Call

AngioDynamics reported strong Q4 fiscal year 2026 results with an 8% revenue increase to $86.6 million, driven by 16.7% growth in its MedTech segment, which now accounts for 47% of total revenue. The company highlighted 20 consecutive quarters of double-digit growth for its Aureon …

AngioDynamics (ANGO) Stock Faces Profitability Question As Q4 EPS Loss Deepens Bearish Narrative

AngioDynamics (ANGO) concluded FY 2026 with a Q4 basic EPS loss of US$0.27 and a full-year basic EPS loss of US$0.88 on US$320.2 million in revenue, continuing a trend of net losses. While forecasts project 72.2% annual earnings growth and profitability within three years, …

J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46

J.P. Morgan has initiated coverage on Tango Therapeutics (TNGX.US) with a 'Buy' rating. The investment bank has also set a target price of $46 for the company's stock.

Freedom Broker raises AngioDynamics stock price target to $17 on margin outlook

Freedom Broker increased its price target for AngioDynamics (NASDAQ: ANGO) to $17.00 from $16.00, reiterating a Buy rating due to an improved margin outlook. This revision follows an upward adjustment of fiscal 2027 adjusted EBITDA estimates by 29% and expectations of growing margins from …

AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands

AngioDynamics (ANGO) reported an adjusted loss per share of 7 cents for Q4 fiscal 2026, which was narrower than analysts' expectations, and full-year fiscal 2026 adjusted loss also beat estimates. The company's Q4 revenues rose 8% year-over-year to $86.6 million, exceeding the Zacks Consensus …

TNGX Initiates Coverage On JP Morgan -- Rating Set to Overweight

JP Morgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and a price target of $46.00. Despite this positive analyst recommendation, GuruFocus indicates that TNGX is significantly overvalued by 202.9%, with a GF Value of $9.79 against a current trading price …

JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.com

JPMorgan initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with an Overweight rating and a $46.00 price target, despite the stock's significant surge and being considered overvalued by InvestingPro analysis. The firm highlighted Tango's progress with its lead PRMT5 inhibitor vopimetostat and advancing combination trials …

JPMorgan Initiates Coverage on Tango Therapeutics With Overweight Rating, $46 Price Target

JPMorgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and set a price target of $46. This positive outlook follows several recent developments for Tango Therapeutics, including its inclusion in various Russell indices. The company specializes in developing precision medicines for …

AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates

AngioDynamics (ANGO) reported a Q4 loss of $0.07 per share, outperforming the Zacks Consensus Estimate of a $0.11 loss, and exceeded revenue expectations with $86.61 million against an $80.16 million estimate. This marks the fourth consecutive quarter the company has surpassed both EPS and …

Sangoma Q2 2026 Earnings: EPS Misses Estimates Significantly Amid Stock Rally - Full Year Guidance

REG - Bango PLC - 1H26 Trading Statement

Cango Inc. (CANG) Gains Nearly 8% as Stock Tests Key Resistance at $0.24 - Entry Point Alerts

CTGO Forecast — Price Target — Prediction for 2027

Cango Inc. Announces Results of Extraordinary General Meeting

Here’s Why Contango Silver & Gold (CTGO) Is One Of The Most Undervalued Silver Mining Stocks To Buy Now

Sangoma Technologies Q1 2026 Earnings: EPS Miss Significantly Exceeds Estimates, Stock Declines 5.6% - Return On Capital

Could Mkango Resources Benefit From Rising Rare Earth Demand?

Cango (CANG) Q1 Loss Deepens Narrative Of Worsening Trailing EPS And Ongoing Unprofitability

Cango Inc. Reports First Quarter 2026 Unaudited Financial Results

Cango Inc. to Report First Quarter 2026 Financial Results on May 31, 2026, Eastern Time

Contango Silver & Gold Inc (CTGO) Q1 2026 Earnings Call Highlights: Navigating Challenges ...

Kavango Resources shares on the move as test data boosts Hillside gold project

Does Contango Silver & Gold (CTGO) Owning Lucky Shot Recast Its Long-Term Development Strategy?

Sangoma Technologies Corporation (TSE:STC) Just Reported Earnings, And Analysts Cut Their Target Price

Contango Silver & Gold Inc. 1Q 2026: Revenue $133.97M, Net loss $(14.31M), EPS $(0.83) — 10-Q Summary

Sangoma Technologies Corporation (SANG) Reports Q3 Loss, Lags Revenue Estimates

Sangoma Announces Third Quarter Fiscal 2026 Results

Mkango Resources Ltd Gains Momentum as Rare Earth Optimism and Strategic Positioning Support Upside Sentiment

Contango Silver & Gold (CTGO) Shares To Start Trading on Toronto Stock Exchange; Analysts Project 45% Upside

Shares slide after Mkango Resources completes £12.5m fundraise, but oversubscription signals longer-term confidence

Cango Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:CANG) 2026-03-23

Contango Announces 2025 Year End Financials and Provides 2026 and 2027 Production Guidance

Cango Inc. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results